Patents by Inventor Piotr Marek SWIDERSKI

Piotr Marek SWIDERSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11912995
    Abstract: Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharmaceutical compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: February 27, 2024
    Assignee: City of Hope
    Inventors: Hua Yu, Andreas Herrmann, Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • Publication number: 20230340479
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Application
    Filed: February 8, 2023
    Publication date: October 26, 2023
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • Publication number: 20230220385
    Abstract: The disclosure provides, inter alia, hybridized nucleic acid sequences and compounds comprising Toll-like receptor 9-binding nucleic acid sequences and nucleic acid sequences comprising a microRNA passenger strand sequence hybridized to a microRNA guide strand sequence; pharmaceutical compositions comprising the hybridized nucleic acid sequences and compounds; and the use of the hybridized nucleic acid sequences, compounds, and pharmaceutical compositions to treat medical conditions, such as cancer and inflammatory diseases.
    Type: Application
    Filed: November 25, 2020
    Publication date: July 13, 2023
    Inventors: Marcin Tomasz Kortylewski, Guido Marcucci, Yu-Lin Su, Piotr Marek Swiderski
  • Publication number: 20230203085
    Abstract: A multi-conjugate comprising two or more covalently linked biological subunits, wherein at least two of the subunits are terminally located targeting ligands. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutic agent that is the multi-conjugate is also disclosed. The multi-conjugate may be administered to a subject for providing treatment or prophylaxis against a disease or other medical condition.
    Type: Application
    Filed: September 1, 2022
    Publication date: June 29, 2023
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Jonathan Miles Brown, Kristin K.H. Neuman
  • Publication number: 20230193258
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Application
    Filed: November 24, 2021
    Publication date: June 22, 2023
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • Patent number: 11591596
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: February 28, 2023
    Assignee: City of Hope
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • Publication number: 20220401563
    Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating an immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
    Type: Application
    Filed: July 14, 2022
    Publication date: December 22, 2022
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
  • Patent number: 11464865
    Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: October 11, 2022
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
  • Publication number: 20220002730
    Abstract: Disclosed herein, inter alia, are oligonucleotide inhibitors of the Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-?B) signaling pathway and methods of use thereof.
    Type: Application
    Filed: August 23, 2019
    Publication date: January 6, 2022
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • Patent number: 11208654
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: December 28, 2021
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • Publication number: 20210330804
    Abstract: Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.
    Type: Application
    Filed: February 24, 2021
    Publication date: October 28, 2021
    Inventors: Andreas HERRMANN, Hua YU, Piotr Marek SWIDERSKI, John Ernest SHIVELY, Lin LI
  • Publication number: 20210269803
    Abstract: Disclosed herein, inter alia, are oligonucleotide-based proteolysis targeting chimeras and methods of use thereof.
    Type: Application
    Filed: June 17, 2019
    Publication date: September 2, 2021
    Inventors: Marcin Kortylewski, Piotr Marek Swiderski, Steven Rosen
  • Publication number: 20210207142
    Abstract: Described herein, inter alia, are STAT-binding nucleic acids-including compositions and methods of using the same.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 8, 2021
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • Publication number: 20210115443
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Application
    Filed: September 2, 2020
    Publication date: April 22, 2021
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • Patent number: 10967070
    Abstract: Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: April 6, 2021
    Assignee: CITY OF HOPE
    Inventors: Andreas Herrmann, Hua Yu, Piotr Marek Swiderski, John Ernest Shively, Lin Li
  • Publication number: 20210038733
    Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
    Type: Application
    Filed: July 24, 2020
    Publication date: February 11, 2021
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
  • Patent number: 10829765
    Abstract: Described herein, inter alia, are STAT-binding nucleic acids-including compositions and methods of using the same.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 10, 2020
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • Patent number: 10801026
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: October 13, 2020
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • Patent number: 10758624
    Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: September 1, 2020
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
  • Publication number: 20200181264
    Abstract: Provided herein relates to antigen-binding molecules, in particular bispecific antigen-binding molecules that bind to a cancer cell antigen and an immune cell surface molecule.
    Type: Application
    Filed: August 10, 2018
    Publication date: June 11, 2020
    Inventors: John J. Rossi, Sarah Yoon, Piotr Marek Swiderski, Nagy Habib, John Ernest Shively